Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Canagliflozin Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 known ✓ | P31639 | 20/20 | 1.00 |
| ▸ | SLC5A1 | P13866 | 6/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Canagliflozin Anhydrous SCHEMBL19293442 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| Canagliflozin Anhydrous SCHEMBL157162 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| Canagliflozin Anhydrous SCHEMBL16075101 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| Canagliflozin Anhydrous SCHEMBL19493514 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| Canagliflozin Anhydrous SCHEMBL873848 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| Canagliflozin Anhydrous SCHEMBL19493519 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| Canagliflozin Anhydrous SCHEMBL24037935 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| Canagliflozin Anhydrous SCHEMBL16421559 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| Canagliflozin Anhydrous SCHEMBL15888791 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| Canagliflozin Anhydrous SCHEMBL19293553 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210163457-A1 | CANAGLIFLOZIN MONOHYDRATE AND ITS CRYSTALLINE FORMS, PREPARATION METHODS AND USES THEREOF | HANGZHOU SOLIPHARMA CO., LTD. (CN) | 2021-06-03 | — | — | US | disclosed |
| US-10954223-B2 | Canagliflozin monohydrate and its crystalline forms, preparation methods and uses thereof | HANGZHOU SOLIPHARMA CO., LTD. (CN) | 2021-03-23 | — | — | US | disclosed |
| US-10544135-B2 | Process for the preparation of compounds useful as inhibitors of SGLT2 | JANSSEN PHARMACEUTICA NV (BE) | 2020-01-28 | — | — | US | disclosed |
| US-20190315727-A1 | CANAGLIFLOZIN MONOHYDRATE AND ITS CRYSTALLINE FORMS, PREPARATION METHODS AND USES THEREOF | HANGZHOU PUSHAI PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2019-10-17 | — | — | US | disclosed |
| US-20170145000-A1 | CANAGLIFLOZIN MONOHYDRATE AND ITS CRYSTALLINE FORMS, PREPARATION METHODS AND USES THEREOF | HANGZHOU PUSHAI PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2017-05-25 | — | — | US | disclosed |
| US-9655852-B2 | Tablets containing a 1-(β-D-glucopyranosyl)-3-(phenylthienylmethyl)benzene compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-05-23 | — | — | US | disclosed |
| US-9024009-B2 | Process for the preparation of compounds useful as inhibitors of SGLT | JANSSEN PHARMACEUTICA N.V. (BE) | 2015-05-05 | — | — | US | disclosed |
| US-20090233874-A1 | PROCESS FOR THE PREPARATION OF COMPOUNDS USEFUL AS INHIBITORS OF SGLT | Tanabe Pharma Corporation (JP) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233874-A1 | PROCESS FOR THE PREPARATION OF COMPOUNDS USEFUL AS INHIBITORS OF SGLT | SLC5A1, SLC5A2, SI | SLC5A2 2/4885SLC5A1 1/4885ABCB11 263/4885 |
| US-10544135-B2 | Process for the preparation of compounds useful as inhibitors of SGLT2 | SLC5A2, SLC5A1, SI | SLC5A2 1/4885SLC5A1 2/4885ABCB11 286/4885 |
| US-20170145000-A1 | CANAGLIFLOZIN MONOHYDRATE AND ITS CRYSTALLINE FORMS, PREPARATION METHODS AND USES THEREOF | SLC5A2, SLC5A1, GCG | SLC5A2 1/4885SLC5A1 2/4885ABCB11 492/4885 |
| US-10954223-B2 | Canagliflozin monohydrate and its crystalline forms, preparation methods and uses thereof | SLC5A2, SLC5A1, GCG | SLC5A2 1/4885SLC5A1 2/4885ABCB11 415/4885 |
| US-20210163457-A1 | CANAGLIFLOZIN MONOHYDRATE AND ITS CRYSTALLINE FORMS, PREPARATION METHODS AND USES THEREOF | SLC5A2, SLC5A1, GCG | SLC5A2 1/4885SLC5A1 2/4885ABCB11 492/4885 |
| US-20190315727-A1 | CANAGLIFLOZIN MONOHYDRATE AND ITS CRYSTALLINE FORMS, PREPARATION METHODS AND USES THEREOF | SLC5A2, SLC5A1, GCG | SLC5A2 1/4885SLC5A1 2/4885ABCB11 415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.